Gene Therapy Trial for Cancer
Phase 2
285
about 9.6 years
18–72
1 site in MD
About this study
This trial is testing a new treatment that involves genetically engineering your own T-cells to fight cancer. It's being done in people whose cancer hasn't responded to standard treatments. The goal is to see if gene therapy can shrink tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Individual Patient TCR-Transduced PBL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Response rate
Endocrinology, Oncology